Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells

Busby, J.; Kim, Sun-Jin; Yazici, MUSTAFA; Nakamura, Toru; Kim, Jang-Seong; He, Junqin; Maya, Marva; Wang, Xuemei; Do, Kim-Anh; Fan, Dominic; Fidler, Isaiah

doi:10.1002/pros.20519

Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells

Busby J. E., Kim S., Yazici S., Nakamura T., Kim J., He J., ...Daha Fazla

PROSTATE, cilt.66, sa.16, ss.1788-1798, 2006 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 66 Sayı: 16
Basım Tarihi: 2006
Doi Numarası: 10.1002/pros.20519
Dergi Adı: PROSTATE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1788-1798
Anahtar Kelimeler: prostate cancer, EGF-R and VEGF-R phosphorylation, antivascular therapy, chemotherapy resistant, angiogenesis, multidrug resistant, LYMPH-NODE METASTASIS, PHASE-II TRIAL, ANTIVASCULAR THERAPY, DUAL INHIBITION, LUNG-CANCER, EXPRESSION, ANGIOGENESIS, CARCINOMA, BLOCKADE, BONE
Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND. Inhibiting epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) activation with AEE788 can decrease prostate cancer (CaP) growth/progression. We determined whether tumor cells or tumor-associated endothelial cells were the primary target by treating multidrug-resistant (MDR) CaP growing in the prostate of nude mice.